Most comprehensive ADC conference dedicated to Asia-Pacific—where decision-makers gather to exchange ideas, celebrate excellence, explore opportunities, and drive business deals

Dr. Paul Song has nearly 30 years of expertise in biotherapeutics drug discovery and development, specializing in immunology and oncology. He is currently the Chief Scientific Officer at GeneQuantum Healthcare in Suzhou, China, where he leads R&D, including new ADC target discovery and the advancement of an innovative bioconjugate pipelines. Dr. Song has been instrumental in establishing GeneQuantum as a global leader in ADCs through cutting-edge technologies.

Previously, he co-founded Curon Bio in Shanghai, China, a biotech venture focused on next-generation immuno-oncology therapeutics, and served as its CSO, laying a strong foundation for the company's rapid growth. He also served as Vice President at Samsung Bioepis in Seoul, Korea, playing a pivotal role in establishing the company as a global leader in biosimilars. Earlier, he was a Principal Research Scientist at Lilly Research Laboratories in Indianapolis, USA. Dr. Song holds a Ph.D. in Biology from Purdue University, USA.

John Flygare is currently Head of the ADC and Large Molecule Innovation Group at Eli Lilly. John has over 25 years of experience in the biotech and pharmaceutical industry. Most recently, John was Chief Scientific Offiicer of Firefly Biologics, a company he co-founded to focus on Degrader-Antibody Conjugates. Prior to FFB, John held leadership roles at Merck and Genentech. John has also lectured extensively at Stanford University where he has taught >30 undergraduate and graduate courses in organic and medicinal chemistry. John has authored or co-authored >100 publications and is an inventor on >50 issued US Patents

Ben is the Vice President of Antibody-Drug Conjugates at Hummingbird Bioscience. With more than 16 years’ experience in the biopharma sector, Ben leads the strategy and development of the Antibody-Drug Conjugates platform and programs at Hummingbird Bioscience. Ben also held strategy and preclinical roles since joining Hummingbird Bioscience in 2020.

Prior to joining Hummingbird Bioscience, Ben advised companies on commercial strategy in APAC at ZS Associates, a healthcare-focused management consulting firm. Ben has accumulated a decade of experience in medicinal chemistry research in a wide range of therapeutic areas including oncology, tropical disease, diabetes, cystic fibrosis, and lysosomal storage diseases at Novartis, the Institute of Cancer Research, and the University of Oxford.

Ben holds a M.Chem. in Chemistry and a D.Phil in Organic Chemistry from the University of Oxford.

Zou Bin is a seasoned executive and has helmed many leadership positions. He is currently an Adjunct Associate Professor at National University of Singapore. Previously, he served as Managing Director at Trinity Innovation Bioventure Singapore (TIBS) and was the CEO of Shanghai Blueray Biopharma where he successfully led the team to develop several candidates into clinic stage. Prior to his venture, Dr. Zou was a Principal Scientist at Novartis Institute for Tropical Disease where he spearheaded the team to the discovery of Phase II clinical trials drug NITD609. He is the author to more than 25 peer reviewed publications.

David Teng-Yi Huang, Ph.D., is Senior Director of ADC Enabling Technologies at OBI Pharma. With expertise in carbohydrate chemistry and glycoengineering, he leads the development of OBI’s proprietary ADC platforms, including GlycOBI®, ThiOBI®, EndoSymeOBI®, and HYPrOBI™. His research focuses on site-specific conjugation, homogeneous ADCs, and novel linker-payload strategies to enhance stability, therapeutic index, and manufacturability. Dr. Huang has advanced multiple clinical and preclinical ADC programs, including dual-payload and bispecific formats, while contributing to OBI’s intellectual property portfolio and business development partnerships. He earned his Ph.D. in Chemistry from National Tsing Hua University and trained at Academia Sinica in glycoscience.

Dr. Moore joined Zymeworks in July 2022 serving as Chief Scientific Officer and heading early stage RnD efforts focused on the development of next generation ADCs and multispecifics, with multiple new therapeutics entered or on track to enter clinical development. Paul has over 25 years of US-based experience in biologics drug discovery and development in biotechnology research, with his career efforts leading to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients. Before joining Zymeworks, Paul served as Vice President, Cell Biology, and Immunology at MacroGenics, where he worked on the development of numerous clinical stage compounds and scientific collaborations with a range of pharmaceutical partners, including Pfizer, Servier, Gilead, Takeda, Janssen, Roche and Zai Labs. He began his biotech career at Human Genome Sciences (HGS), holding several titles within research culminating in Director of Lead Product Development, where he managed various genomic-based target discovery programs including efforts that led to the discovery, development, approval, and commercialization of Benlysta (belimumab) for the treatment of systemic lupus erythematosus. Dr. Moore received a PhD in molecular genetics from the University of Glasgow, performed post-doctoral work at the Roche Institute of Molecular Biology in Nutley, New Jersey, and also holds a degree in Biotechnology from the University of Strathclyde. He has an extensive research record co-authoring over 80 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents.

An experienced and versatile Ph.D. pharmaceutical R&D/Scientific Affairs professional with about 15 years of experience including 8 years as Founder and CEO of Pinotbio, Inc. Experience in drug discovery programs in the areas of oncology – 2 INDs and many on-going pre-clinical programs. Formerly patent examiner in Korea Intellectual Property Office (KIPO) and possesses extensive knowledge about patents and related matters. Has led many scientific evaluations and due diligence of licensing/partnership opportunities in the academic institute and industry in the field of oncology. Extensive knowledge and understanding of drug discovery and preclinical development, especially related to Antibody-Drug Conjugate (ADC) platforms and ADC candidates. Deep understanding of medicinal and process chemistry, especially related with camptothecin payloads and ADC linkers.

Currently, CEO of Pinotbio, Inc. – a South-Korea based biotech company focusing on the discovery and development of novel ADC platforms.

Dr Veronica Diermayr is a molecular biologist with more than 25 years of experience in Translational sciences.

Born and educated in Vienna, Austria, Veronica came to Singapore 25 years ago. She has worked in drug development in the area of immunology and infectious diseases, but her main focus has been in oncology, doing preclinical and clinical development for novel small molecules, biologics and antibody-drug conjugates.

Having worked for an MNC (Novartis), a biotech (S*BIO) where she significantly contributed to the early preclinical and clinical development of the now marketed drug Vonjo (pacritinib), and Singapore-government-funded drug development centres (D3, EDDC), she has deep technical expertise across a wide range of translational work, spanning from animal pharmacology, biomarker research, clinical operations, to CMC. She has been leading multiple therapeutics from discovery through Phase 2 trials. In the past 10 years she has led 3 successful US INDs and 4 Clinical Trial Authorisations in Singapore, that included healthy volunteer studies as well as early phase clinical studies for oncology. Veronica has been leading the EDDC flagship program for the ADC EBC-129 as an Asset Lead for the past 5 years from lead stage into Ph 2 clinical trials with a diagnostic IHC assay developed simultaneously. She’s also leading the Translational Science group overseeing in vivo studies and biomarker development for a novel payload and several novel ADCs and TcEs, including bispecific, bi-paratropic and dual payload ADCs.

Dr. Heidi Wang is an experienced global drug development and regulatory expert with more than 30 years of Pharmaceutical Industry and Biotech experience. With expertise in oncology, virology, immunology and other therapeutic areas, Heidi led and contributed to shaping strategy and delivering approvals for Bristol Myers Squibb Company (BMS) and now, for OBI and OBIGEN.

Importantly, Heidi’s positive leadership style and inclusive mindset helped to transform company’s culture and processes to optimise their portfolio acceleration and to bring people together. Leveraging her strengths in problem solving, risk mitigation and asking the right questions, coupled with a deep expertise in drug development, Heidi is now guiding OBI, OBIGEN and as a Board member of a Taiwan-based company and her alma mater, Fu-Jen University. She also volunteers as an advisor and mentor to individuals and multiple organisations in the US, Europe and Taiwan.

Dr. Changshou Gao is currently CTO and Head of Biologics Research at Shanghai Allist Pharmaceuticals. From 2020–2024, he served as CTO, SVP, and US Site Head at Innovent Biologics, advancing five ADCs and multiple projects into early clinical development. Prior to that, he spent over 18 years at MedImmune/AstraZeneca, leading biologics discovery, bispecific antibodies, ADCs, nnAA platforms, targeted nanoparticles, and AAV gene therapy. His teams advanced more than 20 therapeutic antibodies into clinical trials across oncology, immunology, infectious disease, and metabolic disorders. Dr. Gao earned his Ph.D. in Chemistry and Molecular Biology from The Scripps Research Institute.

Dr. Ee Xien Ng is a Technical Expert and has been with BioReliance® Contract Testing Services, Merck Life Science since 2020. Ee Xien is responsible for supporting technical discussion within internal BioReliance® team and external biopharmaceutical clients on biologics QC testing requirement and consideration. Ee Xien focuses on the discussion around adoption of new testing technologies such as NGS and nucleic acid-based techniques to advance and accelerate biosafety QC testing. Within Merck, Ee Xien had also acted as a GLP Study Director for close to 40 Viral Clearance IND/BLA studies for biopharmaceutical companies across the APAC region and has the relevant knowledge on downstream processing and virology. Before joining Merck, he has experience working on cell manufacturing and micro-bioreactor projects for cell-based therapy with start-up company and researchers from the US and Singapore. Dr. Ng obtained his Ph.D. in Biomedical Engineering from the National University of Singapore and conducted his postdoctoral research on critical analytics for manufacturing personalized medicine at Singapore-MIT Alliance for Research and Technology.

Dr. Jun Hu is currently Head of Client Enabling Center of Excellence and Singapore Site Management at WuXi XDC, by leading a diversified team of talents, including PMs and BDs to help enable global partners’ success on various bioconjugate programs. He is currently leading a team to support construct and manage new manufacturing site at Tuas Singapore. He has nearly 15 years’ comprehensive experience in process development, GMP manufacturing, CMC management, business development, operational excellence as well as team management. Dr. Hu obtained his Ph.D. degree in Bioengineering from Tokyo Institute of Technology, and bachelor’s degree in chemical engineering from Tsinghua University. Before he joined WuXi Biologics/WuXi XDC he was working in Takeda Pharmaceutical Company Japan on process development and clinical GMP manufacturing.

Dr. Pini Tsukerman is an immunologist and co-founder of Nectin Therapeutics, a clinical-stage biotechnology company pioneering next-generation antibody-drug conjugates (ADCs) and immune-oncology therapies. He established Nectin’s R&D organization, built its IP portfolio, and led the company’s scientific and development strategy from inception through clinical proof-of-concept. Under his leadership, Nectin has advanced multiple ADC programs to IND-enabling stages, integrating novel payload and linker technologies, and forged strategic collaborations with leading global biopharmaceutical companies to accelerate development. Dr. Tsukerman also guided the company’s lead program, NTX1088, from concept to clinical validation, advancing Nectin’s mission to deliver transformative therapies for resistant cancers.

Dr. Chuang received his PhD degree in Medicinal Chemistry from National Tsing Hua University. As a principal investigator in Development Center for Biotechnology (DCB), he led several drug discovery projects especially on oncology field. These topics include Top1 inhibitor, Nek2/Hec1 inhibitor, antibody-drug conjugates (ADC) and proteolysis targeting chimera (PROTAC). After more than 15 years, he left DCB and joined OBI Pharma as the director of Medicinal Chemistry and focusing on developing anti-Trop2 ADC. In 2022, Dr. Chuang co-founded HoneyBear Biosciences, and serve as the CEO.